Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Clinical Pharmacology"
DOI: 10.1007/s00228-017-2378-0
Abstract: Consideration of drug benefits and harms is asymmetric. Approval of drugs is mainly based on efficacy, while the assessment of their safety is left to post-marketing commitments or spontaneous reporting. Benefits are overestimated as a… read more here.
Keywords: overlooking harms; benefits risk; risk stop; benefits benefits ... See more keywords